Global Renal Cell Carcinoma Therapy Devices Market Insights, Forecast to 2028

Renal cell carcinoma (RCC) is increasing in incidence and one third of newly diagnosed cases already are metastatic. The metastatic spread of solid tumors renders RCC incurable by surgical resection and consequently more difficult to treat. New molecular-targeted therapies have played a pivotal role in RCC treatment.
Market Analysis and Insights: Global Renal Cell Carcinoma Therapy Devices Market
The global Renal Cell Carcinoma Therapy Devices market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Directed Energy-based Therapy Devices accounting for % of the Renal Cell Carcinoma Therapy Devices global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Renal Cell Carcinoma Therapy Devices market size is valued at US$ million in 2021, while the North America and Europe Renal Cell Carcinoma Therapy Devices are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Renal Cell Carcinoma Therapy Devices landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Renal Cell Carcinoma Therapy Devices market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Renal Cell Carcinoma Therapy Devices market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Renal Cell Carcinoma Therapy Devices market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Renal Cell Carcinoma Therapy Devices market.
Global Renal Cell Carcinoma Therapy Devices Scope and Market Size
Renal Cell Carcinoma Therapy Devices market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Renal Cell Carcinoma Therapy Devices market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Directed Energy-based Therapy Devices
Drug/Fluid Delivery and Infusion Therapy Devices
Segment by Application
Hospital
Clinic
By Company
AngioDynamics, Inc.
Boston Scientific Corporation (Galil Medical, Inc.)
IceCure Medical
HealthTronics, Inc.
HistoSonics, Inc.
Integra LifeSciences Holdings Corporation
Medtronic plc
Monteris Medical, Inc.
Novocure GmbH
Varian Medical Systems, Inc.
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA